Patients undergoing orthotropic liver transplant (LTx) often present with chronic kidney disease (CKD). Identification of patients who will progress to end-stage renal disease (ESRD) might allow not only the implementation of kidney protective measures but also simultaneous kidney transplant.
Study Design
Retrospective cohort study in adults who underwent LTx at a single center. ESRD, death, and composite of ESRD or death were studied outcomes.
Results
331 patients, who underwent LTx, were followed up for 2.6 ± 1.4 years; 31 (10%) developed ESRD, 6 (2%) underwent kidney transplant after LTx and 25 (8%) remained on chronic hemodialysis. Patients with pre-operative eGFR lesser than 60 ml/min per 1.73 m2 had a 4-fold increased risk of developing ESRD after adjustment for sex, diabetes mellitus, APACHE II score, use of nephrotoxic drugs, and severe liver graft failure (HR = 3.95, 95% CI 1.73, 9.01; p = 0.001). Other independent risk factors for ESRD were pre-operative diabetes mellitus and post-operative severe liver graft dysfunction.
Conclusion
These findings emphasize low eGFR prior to LTx as a predictor for ESRD or death. The consideration for kidney after liver transplant as a treatment modality should be taken into account for those who develop chronic kidney failure after LTx.
SabryA.A., SobhM.A., IrvingW.L.A comprehensive study of the association between hepatitis C virus and glomerulopathy.Nephrol Dial Transplant.2002; 17(2): 239–245.
2.
HamelM.B., PhillipsR.S., DavisR.B.; SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults.Ann Intern Med.1997; 127(3): 195–202.
3.
OjoA.O., HeldP.J., PortF.K.Chronic renal failure after transplantation of a nonrenal organ.N Engl J Med.2003; 349(10): 931–940.
4.
GonwaT.A., MaiM.L., MeltonL.B.End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.Transplantation.2001; 72(12): 1934–1939.
5.
DavisC.L., GonwaT.A., WilkinsonA.H.Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I.Liver Transpl.2002; 8(2): 91–109.
6.
DavisC.L., GonwaT.A., WilkinsonA.H.Identification of patients best suited for combined liver-kidney transplantation: part II.Liver Transpl.2002; 8(3): 193–211.
7.
KamathP.S., WiesnerR.H., MalinchocM.A model to predict survival in patients with end-stage liver disease.Hepatology.2001; 33(2): 464–470.
8.
LevyM.M., FinkM.P., MarshallJ.C.; International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.Intensive Care Med.2003; 29(4): 530–538.
9.
MehtaR.L., KellumJ.A., ShahS.V.; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.Crit Care.2007; 11(2): R31.
10.
GonzálezF.X., RimolaA., GrandeL.Predictive factors of early postoperative graft function in human liver transplantation.Hepatology.1994; 20(3): 565–573.
11.
D'AlessandroA.M., PloegR.J., KnechtleS.J.Retransplantation of the liver–a seven-year experience.Transplantation.1993; 55(5): 1083–1087.
12.
LeveyA.S., BoschJ.P., LewisJ.B., GreeneT., RogersN., RothD; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.Ann Intern Med.1999; 130(6): 461–470.
13.
National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Am J Kidney Dis.2002; 39(2)(Suppl 1): S1–S266.
14.
RettkeS.R., JanossyT.A., ChantigianR.C.Hemodynamic and metabolic changes in hepatic transplantation.Mayo Clin Proc.1989; 64(2): 232–240.
15.
WalserM., DrewH.H., LaFranceN.D.Creatinine measurements often yielded false estimates of progression in chronic renal failure.Kidney Int.1988; 34: 412–418.
16.
KennyD.A study of interferences in routine methods for creatinine measurement.Scand J Clin Lab Invest Suppl.1993; 212: 43–47.
17.
GlassockR.J., WinearlsC.Screening for CKD with eGFR: doubts and dangers.Clin J Am Soc Nephrol.2008; 3(5): 1563–1568.
18.
FreemanR.B.Jr.Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card.Hepatology.2008; 47(3): 1052–1057.
19.
FisherN.C., NightingaleP.G., GunsonB.K., LipkinG.W., NeubergerJ.M.Chronic renal failure following liver transplantation: a retrospective analysis.Transplantation.1998; 66(1): 59–66.
20.
OjoA.O.Renal disease in recipients of nonrenal solid organ transplantation.Semin Nephrol.2007; 27(4): 498–507.
21.
ParameshA.S., RoayaieS., DoanY.Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease.Clin Transplant.2004; 18(1): 94–99.
22.
de BoccardoG., KimJ.Y., SchianoT.D.The burden of chronic kidney disease in long-term liver transplant recipients.Transplant Proc.2008; 40(5): 1498–1503.
SanchezE.Q., GonwaT.A., LevyM.F.Pre-Operative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation.Transplantation.2004; 78(7): 1048–1054.
25.
GonwaT.A., KlintmalmG.B., LevyM., JenningsL.S., GoldsteinR.M., HusbergB.S.Impact of pretransplant renal function on survival after liver transplantation.Transplantation.1995; 59(3): 361–365.
YoungelmanD.F., KahngK.U., RosenB.D., DresnerL.S., WaitR.B.Effects of chronic cyclosporine administration on renal blood flow and intrarenal blood flow distribution.Transplantation.1991; 51(2): 503–509.
28.
EspositoC., FoschiA., ParrillaB.Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli.Transplant Proc.2004; 36(3): 695–697.
29.
TanrioverB., MejiaA., WeinsteinJ.Analysis of kidney function and biopsy results in liver failure patients with renal dysfunction: a new look to combined liver kidney allocation in the post-MELD era.Transplantation.2008; 86(11): 1548–1553.
30.
JainA., VekatramananR., EghtesadB.Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation.Transplantation.2005; 80(6): 859–864.
